Search Results - "Riedel, R. F."

Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development by Luetteke, N C, Qiu, T H, Fenton, S E, Troyer, K L, Riedel, R F, Chang, A, Lee, D C

“…Targeted mice lacking functional EGF or amphiregulin (AR) were derived and bred to the TGFalpha-knockout to generate mice lacking various combinations of the…”
Get full text

216 IDENTIFYING MECHANISMS OF RESISTANCE IN PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER RECEIVING DOSE-DENSE NEOADJUVANT/INDUCTION CHEMOTHERAPY by Riedel, R. F., Febbo, P. G., Crawford, J.

“…IntroductionThe current treatment of locally advanced non-small cell lung cancer (NSCLC) is debated. Induction strategies with dose-dense chemotherapy may…”
Get full text

Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant by Salomoni, P, Wasik, M A, Riedel, R F, Reiss, K, Choi, J K, Skorski, T, Calabretta, B

“…The oncogenic BCR/ABL protein protects hematopoietic cells from apoptosis induced by growth factor deprivation, but the mechanisms are only partially…”
Get full text

Characterization of the mouse transforming growth factor α gene : Its expression during eyelid development and in waved 1 tissues by BERKOWITZ, E. A, SEROOGY, K. B, SCHROEDER, J. A, RUSSELL, W. E, EVANS, E. P, RIEDEL, R. F, PHILLIPS, H. K, HARRISON, C. A, LEE, D. C, LUETTEKE, N. C

“…The spontaneous mouse waved 1 (wa1) mutation is allelic with the transforming growth factor alpha (TGF-alpha) gene and produces phenotypes similar to those of…”
Get full text

A genomic approach to identify therapeutic targets in histologic subtypes of soft tissue sarcoma by Riedel, R. F., Friedman, D., Febbo, P. G.

“…Abstract only…”
Get full text

Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT) by Chawla, S. P., Blay, J., Ray-Coquard, I. L., Le Cesne, A., Staddon, A. P., Milhem, M. M., Penel, N., Riedel, R. F., Bui Nguyen, B., Cranmer, L. D., Reichardt, P., Bompas, E., Song, Y., Lee, R., Eid, J. E., Loewy, J., Haluska, F. G., Dodion, P. F., Demetri, G. D.

“…Abstract only…”
Get full text

A genomic approach to identify mechanisms associated with chemotherapy resistance by Riedel, R. F., Porrello, A., Chenette, E., Potti, A., Nevins, J. R., Febbo, P. G.

“…Abstract only 2534 Background: Gene expression profiling has shown an ability to predict chemotherapeutic response (Potti et al. Nature Medicine 2006)…”
Get full text

Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors by Howard, L. A., Bullock, K. E., Bendell, J. C., Uronis, H. E., Vlahovic, G., Blobe, G. C., Riedel, R. F., Nixon, A. B., Gockerman, J. P., Hurwitz, H. I.

“…Abstract only 3551 Background: In preclinical models, VEGF, mTOR, and EGFR inhibitors have anti-tumor and anti-angiogenesis effects as monotherapies and in…”
Get full text

Use of co-activation of lung cancer specific developmental pathway genes, TTF-1, NKX2–8, and PAX9, to predict prognosis and guide therapeutic strategies by Hsu, S. D., Acharya, C. R., Riedel, R. F., Redman, R. C., Garman, K. S., Dressman, H. K., Ginsburg, G., Powers, S., Mu, D., Potti, A.

“…Abstract only…”
Get full text

IDENTIFYING MECHANISMS OF RESISTANCE IN PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER RECEIVING DOSE-DENSE NEOADJUVANT/INDUCTION CHEMOTHERAPY: 216 by Riedel, R. F., Febbo, P. G., Crawford, J.

Get full text